New clinical evidence supporting Asserachrom HPIA-IgG in HIT diagnosis

Conducted across five French centres, the study included 170 consecutive patients with an intermediate or high clinical probability of HIT, making it a robust evaluation in a clinically relevant population.
 

Strong diagnostic performance in patients with suspected HIT

At the manufacturer’s recommended cut-off of 0.18 OD, Asserachrom HPIA-IgG demonstrated 100% sensitivity and 100% negative predictive value, confirming its excellent ability to help exclude HIT when the result is negative. 

The study also reported 76.4% specificity and 58.9% positive predictive value at this cut-off.

Quantitative OD assessment adds value to result interpretation

Beyond the positive/negative interpretation at the manufacturer’s cut-off, quantitative OD assessment among positive samples may help laboratories better stratify positive results. Stronger OD signals were associated with a higher likelihood of functionally confirmed HIT, supporting more specific interpretation of positive immunoassay results.

Together with existing clinical evidence supporting STic Expert HIT, Stago’s rapid immunoassay for anti-PF4/heparin antibodies, these findings further illustrate the value of complementary Stago solutions in the diagnostic work-up of suspected HIT.